SCHEMBL2965844

SCHEMBL2965844

COCCCN1CCN(Cc2ccc(-n3nc(-c4ccc5c(ccn5Cc5ccccc5Cl)c4)c4c(N)ncnc43)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.48
▸ ERBB2 P04626 4/20 0.48
▸ IGF1R P08069 4/20 0.48
▸ CYP2D6 P10635 1/20 0.43
▸ ERBB3 P21860 2/20 0.42
▸ ERBB4 Q15303 2/20 0.42
▸ SRC P12931 13/20 0.42
▸ ABL1 P00519 3/20 0.38
▸ PIK3CD O00329 3/20 0.38
▸ PIK3CA P42336 3/20 0.38
▸ PIK3CB P42338 3/20 0.38
▸ PIK3CG P48736 3/20 0.38
▸ PRKDC P78527 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ HCK P08631 2/20 0.38
▸ MTOR P42345 2/20 0.38
▸ EPHB4 P54760 2/20 0.38
▸ RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956385 0.85 KDR (0.51) EGFRERBB2IGF1RSRCABL1
SCHEMBL2954055 0.85 EGFR (0.61) EGFRERBB2IGF1RCYP2D6ERBB3
SCHEMBL2954052 0.85 EGFR (0.61) EGFRERBB2IGF1RCYP2D6ERBB3
SCHEMBL2957797 0.85 EGFR (0.61) EGFRERBB2IGF1RCYP2D6ERBB3
SCHEMBL2962359 0.82 PIK3CD (0.44) EGFRERBB2IGF1RSRCABL1
SCHEMBL2961198 0.79 EGFR (0.56) EGFRERBB2IGF1RCYP2D6ERBB3
SCHEMBL2962688 0.79 IGF1R (0.44) EGFRERBB2IGF1RSRCABL1
SCHEMBL2969399 0.77 TGFBR1 (0.44) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2969401 0.77 TGFBR1 (0.44) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2955893 0.77 IGF1R (0.61) EGFRERBB2IGF1RCYP2D6ERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 EGFR 591/4885ERBB2 270/4885IGF1R 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback